Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 7
1976 7
1978 4
1979 1
1980 1
1981 12
1982 8
1983 4
1984 12
1985 11
1986 5
1987 8
1988 5
1989 4
1990 9
1991 10
1992 13
1993 19
1994 11
1995 12
1996 10
1997 13
1998 9
1999 9
2000 11
2001 9
2002 12
2003 11
2004 14
2005 15
2006 9
2007 22
2008 19
2009 11
2010 21
2011 14
2012 12
2013 12
2014 13
2015 8
2016 3
2017 6
2018 7
2019 11
2020 12
2021 7
2022 5
2023 6
2024 7
2025 11
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

467 results

Results by year

Filters applied: . Clear all
Page 1
Naltrexone Implant for Opioid Use Disorder.
Edinoff AN, Nix CA, Orellana CV, StPierre SM, Crane EA, Bulloch BT, Cornett EM, Kozinn RL, Kaye AM, Murnane KS, Kaye AD. Edinoff AN, et al. Neurol Int. 2021 Dec 30;14(1):49-61. doi: 10.3390/neurolint14010004. Neurol Int. 2021. PMID: 35076607 Free PMC article. Review.
Patients that routinely take their naltrexone reported fewer days of heroin use and had more negative drug tests than those without treatment. ...The latter study also concluded that there was no increased risk for mental health-related incidents in patients taking …
Patients that routinely take their naltrexone reported fewer days of heroin use and had more negative drug tests than those wi …
Medication Treatment of Opioid Use Disorder.
Bell J, Strang J. Bell J, et al. Biol Psychiatry. 2020 Jan 1;87(1):82-88. doi: 10.1016/j.biopsych.2019.06.020. Epub 2019 Jul 2. Biol Psychiatry. 2020. PMID: 31420089 Review.
Naltrexone blocks the effects of opioid agonists. Oral methadone has the strongest evidence for effectiveness. ...Treatment with methadone and buprenorphine has the additional risk of diversion and misuse of medication. New depot and implant formulations of buprenor …
Naltrexone blocks the effects of opioid agonists. Oral methadone has the strongest evidence for effectiveness. ...Treatment with meth …
Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.
Krupitsky E, Blokhina E, Zvartau E, Verbitskaya E, Lioznov D, Yaroslavtseva T, Palatkin V, Vetrova M, Bushara N, Burakov A, Masalov D, Mamontova O, Langleben D, Poole S, Gross R, Woody G. Krupitsky E, et al. Lancet HIV. 2019 Apr;6(4):e221-e229. doi: 10.1016/S2352-3018(18)30362-X. Epub 2019 Mar 14. Lancet HIV. 2019. PMID: 30880163 Free PMC article. Clinical Trial.
BACKGROUND: Untreated opioid addiction in people with HIV is associated with poor HIV treatment outcomes. Slow-release, long-acting, implantable naltrexone might improve these outcomes. Here, we present results of a study aimed to test this hypothesis. ...We stratif …
BACKGROUND: Untreated opioid addiction in people with HIV is associated with poor HIV treatment outcomes. Slow-release, long-acting, impl …
Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review.
Duah J, Seifer DB. Duah J, et al. Reprod Biol Endocrinol. 2025 Jan 6;23(1):2. doi: 10.1186/s12958-024-01339-y. Reprod Biol Endocrinol. 2025. PMID: 39762910 Free PMC article. Review.
Adverse conception outcomes are multifactorial, ranging from poor oocyte quality and implantation issues to miscarriages and fetal health issues. However, with the advent of novel pharmacologic agents, significant weight loss can be achieved, improving the chances of healt …
Adverse conception outcomes are multifactorial, ranging from poor oocyte quality and implantation issues to miscarriages and fetal he …
Managing Burning Mouth Syndrome: Current and Future Directions.
Sangalli L, Mirfarsi S, Kramer JM, Eisa E, Miller CS. Sangalli L, et al. Drugs. 2025 Sep;85(9):1109-1131. doi: 10.1007/s40265-025-02220-x. Epub 2025 Aug 15. Drugs. 2025. PMID: 40815383 Review.
Current management strategies range from addressing underlying systemic or local factors to utilizing established systemic or topical pharmacologic options (such as benzodiazepines, capsaicin, anticonvulsants, antidepressants), new off-label treatments (including low-dose nalt …
Current management strategies range from addressing underlying systemic or local factors to utilizing established systemic or topical pharma …
A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.
Kelty E, Hulse G. Kelty E, et al. Drugs. 2017 Jul;77(11):1199-1210. doi: 10.1007/s40265-017-0762-9. Drugs. 2017. PMID: 28536980

Birth rates in women on naltrexone implant treatment were significantly higher than in all three comparison groups (p < 0.001). ...Overall rates of complications during pregnancy were significantly higher in the naltrexone-treated women than in the control

…

Birth rates in women on naltrexone implant treatment were significantly higher than in all three comparison groups (p < 0.0

…
Naltrexone implants.
Kelly KI, McBride A. Kelly KI, et al. Br J Psychiatry. 2010 Jan;196(1):77; author reply 77. doi: 10.1192/bjp.196.1.77. Br J Psychiatry. 2010. PMID: 20044669 No abstract available.
Comparison of naltrexone implant and oral buprenorphine-naloxone in the treatment of opiate use disorder.
Erdoğan A, Topcuoğlu M, Coşkun MN, Cinemre B, Kulaksızoğlu B, Kuloğlu MM. Erdoğan A, et al. Hum Psychopharmacol. 2022 Mar;37(2):e2813. doi: 10.1002/hup.2813. Epub 2021 Sep 17. Hum Psychopharmacol. 2022. PMID: 34532895
OBJECTIVE: We aimed to compare the effectiveness of extended-release naltrexone (XR-NTX) implant and sublingual buprenorphine-naloxone (BUP-NX) in relapse prevention in opiate use disorder (OUD). ...
OBJECTIVE: We aimed to compare the effectiveness of extended-release naltrexone (XR-NTX) implant and sublingual buprenorphine- …
Retention in naltrexone implant treatment for opioid dependence.
Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen O, Waal H. Kunøe N, et al. Drug Alcohol Depend. 2010 Sep 1;111(1-2):166-9. doi: 10.1016/j.drugalcdep.2010.03.021. Epub 2010 May 31. Drug Alcohol Depend. 2010. PMID: 20570059
BACKGROUND: Naltrexone's usefulness in the treatment of opioid dependence stems from its ability to block the action of heroin and other opioids. ...METHODS: Patients (n=61) receving treatment with sustained release naltrexone implants were offered a s …
BACKGROUND: Naltrexone's usefulness in the treatment of opioid dependence stems from its ability to block the action of heroin …
[Naltrexone implant treatment of polydrug dependence].
Krupitskiĭ EM, Blokhina EA, Verbitskaia EV, Mamontova OV, Zvartau EE, Tiikhonen Ia. Krupitskiĭ EM, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(5 Pt 2):39-45. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PMID: 24988974 Russian.
Objective. Recent studies indicate that naltrexone implant may be one of the effective pharmacological treatments for opiate dependence. ...At week 10, the retention was 52% among patients with naltrexone vs. 28% among patients with placebo implant (p= …
Objective. Recent studies indicate that naltrexone implant may be one of the effective pharmacological treatments for opiate d …
467 results